Sellas Life Sciences Group Financial Results
SELLAS Life Sciences reported its third quarter 2026 financial results, highlighting a cash position of $134.7 million. The company expects to report topline primary endpoint results from its Phase 3 REGAL trial of GPS in AML later this month and preliminary topline data for SLS009 in first-line AML in Q4 2026.
- Term
- Q3 2026
“We continue to execute across both of our clinical programs as we approach several important milestones. In our ongoing Phase 3 REGAL trial of GPS, we are focused on completing the final analysis following the announcement of 80th event, and we expect to announce topline primary endpoint results this month. If successful, we believe GPS could be a transformative new immunotherapy for AML patients in second complete remission.”
Angelos Stergiou, MD, ScD h.c., President and Chief Executive Officer
“In parallel, enrollment and dosing continue in our Phase 2 trial of tambiciclib (SLS009) in newly diagnosed AML, with preliminary topline data expected in the fourth quarter. As announced earlier this month, we look forward to presenting our Phase 2 data in relapsed/refractory AML at the upcoming ASH in December. We were also encouraged by the preclinical data presented at AACR in pancreatic cancer models, including in resistance to a RAS inhibitor, and we are continuing our preparations for clinical development in that indication. With $134.7 million in cash and cash equivalents as of September 30, we are well positioned to further advance these programs.”
Angelos Stergiou, MD, ScD h.c., President and Chief Executive Officer